LJPC
Income statement / Annual
Last year (2021), La Jolla Pharmaceutical Company's total revenue was $75.72 M,
an increase of 126.58% from the previous year.
In 2021, La Jolla Pharmaceutical Company's net income was $19.66 M.
See La Jolla Pharmaceutical Company,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
| Operating Revenue |
$75.72 M |
$33.42 M |
$23.05 M |
$10.06 M |
$0.00 |
$616,000.00 |
$1.06 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$13.49 M
|
$7.82 M
|
$2.39 M
|
$1.64 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$62.23 M
|
$25.60 M
|
$20.66 M
|
$8.41 M
|
$0.00
|
$616,000.00
|
$1.06 M
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.82
|
0.77
|
0.9
|
0.84
|
0
|
1
|
1
|
0
|
0
|
0
|
| Research and Development Expenses |
$5.01 M
|
$23.01 M
|
$85.33 M
|
$117.30 M
|
$84.58 M
|
$62.29 M
|
$29.09 M
|
$9.94 M
|
$4.36 M
|
$1.35 M
|
| General & Administrative Expenses |
$29.77 M
|
$34.51 M
|
$37.94 M
|
$61.23 M
|
$30.85 M
|
$16.70 M
|
$13.93 M
|
$11.40 M
|
$13.58 M
|
$9.39 M
|
| Selling & Marketing Expenses |
$5.62 M
|
$3.92 M
|
$7.19 M
|
$23.93 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$35.39 M
|
$38.43 M
|
$45.13 M
|
$85.16 M
|
$30.85 M
|
$16.70 M
|
$13.93 M
|
$11.40 M
|
$13.58 M
|
$9.39 M
|
| Other Expenses |
$8.98 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$40.40 M
|
$61.44 M
|
$130.46 M
|
$202.46 M
|
$115.43 M
|
$78.99 M
|
$43.03 M
|
$21.34 M
|
$17.94 M
|
$10.74 M
|
| Cost And Expenses |
$53.89 M
|
$69.26 M
|
$132.86 M
|
$204.11 M
|
$115.43 M
|
$78.99 M
|
$43.03 M
|
$21.34 M
|
$17.94 M
|
$10.74 M
|
| Interest Income |
$7,000.00
|
$235,000.00
|
$2.13 M
|
$1.89 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$10.46 M
|
$10.05 M
|
$10.77 M
|
$7.30 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$1.88 M
|
$4.08 M
|
$4.55 M
|
$4.41 M
|
$1.27 M
|
$730,000.00
|
$347,000.00
|
$17,000.00
|
$5,000.00
|
$3.00 M
|
| EBITDA |
$32.05 M |
-$35.84 M |
-$109.80 M |
-$187.76 M |
-$115.43 M |
-$78.37 M |
-$41.97 M |
-$21.34 M |
-$17.94 M |
-$7.74 M |
| EBITDA Ratio |
0.42
|
-0.76
|
-4.39
|
-18.67
|
0
|
-125.74
|
-39.32
|
0
|
0
|
0
|
| Operating Income Ratio |
0.4
|
-1.07
|
-4.76
|
-19.3
|
0
|
-127.23
|
-39.71
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$2.12 M
|
-$3.58 M
|
-$6.71 M
|
-$5.42 M
|
$624,000.00
|
$187,000.00
|
$57,000.00
|
$27,000.00
|
$4,000.00
|
$3.00 M
|
| Income Before Tax |
$19.71 M
|
-$39.42 M
|
-$116.51 M
|
-$199.47 M
|
-$114.80 M
|
-$78.19 M
|
-$41.91 M
|
-$21.31 M
|
-$17.94 M
|
-$7.74 M
|
| Income Before Tax Ratio |
0.26
|
-1.18
|
-5.05
|
-19.84
|
0
|
-126.92
|
-39.65
|
0
|
0
|
0
|
| Income Tax Expense |
$49,000.00
|
$6.47 M
|
$4.07 M
|
$1.89 M
|
$624,000.00
|
$187,000.00
|
$57,000.00
|
$27,000.00
|
$4,000.00
|
$0.00
|
| Net Income |
$19.66 M
|
-$39.42 M
|
-$116.51 M
|
-$199.47 M
|
-$114.80 M
|
-$78.19 M
|
-$41.91 M
|
-$21.31 M
|
-$17.94 M
|
-$7.74 M
|
| Net Income Ratio |
0.26
|
-1.18
|
-5.05
|
-19.84
|
0
|
-126.92
|
-39.65
|
0
|
0
|
0
|
| EPS |
0.58 |
-1.44 |
-4.3 |
-7.85 |
-5.41 |
-4.54 |
-2.68 |
-2 |
-39.48 |
-37.94 |
| EPS Diluted |
0.58 |
-1.44 |
-4.3 |
-7.85 |
-5.41 |
-4.54 |
-2.68 |
-2 |
-39.48 |
-37.94 |
| Weighted Average Shares Out |
$34.18 M
|
$27.33 M
|
$27.11 M
|
$25.42 M
|
$21.22 M
|
$17.23 M
|
$15.65 M
|
$10.67 M
|
$454,337.00
|
$203,920.00
|
| Weighted Average Shares Out Diluted |
$34.18 M
|
$27.33 M
|
$27.11 M
|
$25.42 M
|
$21.22 M
|
$17.23 M
|
$15.65 M
|
$10.67 M
|
$454,337.00
|
$203,920.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
